Aeterna Zentaris Inc. (NASDAQ:AEZS – Get Free Report) (TSE:AEZ) was the recipient of a large decrease in short interest in the month of April. As of April 15th, there was short interest totalling 16,900 shares, a decrease of 22.1% from the March 31st total of 21,700 shares. Based on an average daily volume of 15,900 shares, the short-interest ratio is currently 1.1 days. Approximately 0.4% of the shares of the company are sold short.
Analyst Upgrades and Downgrades
Separately, StockNews.com initiated coverage on shares of Aeterna Zentaris in a research report on Monday, April 22nd. They set a “sell” rating for the company.
View Our Latest Research Report on AEZS
Aeterna Zentaris Stock Performance
Aeterna Zentaris (NASDAQ:AEZS – Get Free Report) (TSE:AEZ) last posted its quarterly earnings data on Wednesday, March 27th. The biopharmaceutical company reported ($1.16) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.19). The company had revenue of $0.12 million during the quarter. Aeterna Zentaris had a negative return on equity of 63.20% and a negative net margin of 368.01%.
About Aeterna Zentaris
Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults.
Further Reading
- Five stocks we like better than Aeterna Zentaris
- What Are Trending Stocks? Trending Stocks Explained
- Snap Crackles and Pops on Surprise Profit and Raised Guidance
- What Does a Stock Split Mean?
- MarketBeat Week in Review – 4/22 – 4/26
- What Are Dividend Challengers?
- 3 Stocks Leading the U.S. Agriculture Comeback
Receive News & Ratings for Aeterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.